- Home
- FCCO vs CGON Comparison
FCCO vs CGON Comparison
Compare FCCO & CGON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCCO
- CGON
- Stock Information
- Founded
- FCCO 1994
- CGON 2010
- Country
- FCCO United States
- CGON United States
- Employees
- FCCO N/A
- CGON N/A
- Industry
- FCCO Major Banks
- CGON
- Sector
- FCCO Finance
- CGON
- Exchange
- FCCO Nasdaq
- CGON NYSE
- Market Cap
- FCCO N/A
- CGON 1.3B
- IPO Year
- FCCO 1998
- CGON 2024
- Fundamental
- Price
- FCCO $23.86
- CGON $24.13
- Analyst Decision
- FCCO Strong Buy
- CGON Strong Buy
- Analyst Count
- FCCO 2
- CGON 11
- Target Price
- FCCO $30.00
- CGON $62.90
- AVG Volume (30 Days)
- FCCO 27.7K
- CGON 2.0M
- Earning Date
- FCCO 04-23-2025
- CGON 05-16-2025
- Dividend Yield
- FCCO 2.53%
- CGON N/A
- EPS Growth
- FCCO 37.48
- CGON N/A
- EPS
- FCCO 1.98
- CGON N/A
- Revenue
- FCCO $67,933,000.00
- CGON $1,139,000.00
- Revenue This Year
- FCCO $16.14
- CGON N/A
- Revenue Next Year
- FCCO $8.59
- CGON $16,237.24
- P/E Ratio
- FCCO $11.97
- CGON N/A
- Revenue Growth
- FCCO 16.46
- CGON 461.08
- 52 Week Low
- FCCO $15.75
- CGON $14.80
- 52 Week High
- FCCO $27.96
- CGON $40.47
- Technical
- Relative Strength Index (RSI)
- FCCO 58.03
- CGON 51.00
- Support Level
- FCCO $23.60
- CGON $21.00
- Resistance Level
- FCCO $24.93
- CGON $30.23
- Average True Range (ATR)
- FCCO 0.81
- CGON 2.31
- MACD
- FCCO 0.13
- CGON 0.16
- Stochastic Oscillator
- FCCO 76.84
- CGON 34.09
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.